Valuation: Avalo Therapeutics, Inc.

Market Cap 97Cr 84Cr 78Cr 72Cr 135.6Cr 9.2TCr 137.97Cr 923.72Cr 361.77Cr 4.59TCr 362.65Cr 354.62Cr 15TCr P/E 2026 *
-7.39x
P/E 2027 * -6.1x
Enterprise Value 55Cr 47Cr 44Cr 41Cr 77Cr 5.21TCr 78Cr 522.46Cr 204.62Cr 2.6TCr 205.12Cr 200.58Cr 8.56TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.28%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-0.68%
1 week-7.44%
Current month-1.10%
1 month-9.57%
3 months+30.99%
6 months+13.10%
Current year-0.61%
1 week 17.75
Extreme 17.75
19.97
1 month 17.54
Extreme 17.54
20.65
Current year 12.51
Extreme 12.51
24.27
1 year 7.87
Extreme 7.87
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-7.44%+101.23%-61.98% 97Cr
+0.05%+2.80%+38.17%+74.12% 5.65TCr
-3.06%-8.56%+22.91%+58.73% 5.36TCr
+2.61%+1.88%-15.66%-12.99% 2.29TCr
+0.19%-6.12%-11.61%+343.88% 2.14TCr
+0.15%-0.77%+23.76%-11.52% 2.03TCr
-0.67%-3.25%+30.55%-29.84% 1.76TCr
-1.45%-7.24%+17.67%+563.14% 1.47TCr
+9.91%+2.64%+188.84%+326.19% 1.35TCr
+2.99%-2.19%+48.30%+162.96% 1.33TCr
Average +1.02%-1.80%+44.42%+141.27% 2.35TCr
Weighted average by Cap. +0.21%-1.70%+31.32%+121.21%

Financials

2026 *2027 *
Net sales - -
Net income -8.57Cr -7.45Cr -6.96Cr -6.39Cr -12Cr -817.07Cr -12Cr -82Cr -32Cr -407.46Cr -32Cr -31Cr -1.34TCr -11Cr -9.6Cr -8.96Cr -8.22Cr -16Cr -1.05TCr -16Cr -105.64Cr -41Cr -524.83Cr -41Cr -41Cr -1.73TCr
Net Debt -42Cr -36Cr -34Cr -31Cr -59Cr -4TCr -60Cr -401.26Cr -157.15Cr -1.99TCr -157.54Cr -154.05Cr -6.58TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.91TCr -44Cr -291.95Cr -114.34Cr -1.45TCr -114.62Cr -112.08Cr -4.78TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
04/26/04 $18.09 -0.88% 3,03,533
31/26/31 $18.25 -5.88% 9,23,877
30/26/30 $19.39 +2.00% 9,35,221
29/26/29 $19.01 -2.61% 7,89,787
28/26/28 $19.52 +0.10% 8,15,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.25USD
Average target price
44.69USD
Spread / Average Target
+144.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock